Ultragenyx Pharmaceutical Inc.
HealthcareNASDAQ:RARE · NASDAQ Global Select
+$0.37 today
Vol 1.85M · Avg 1.81M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$575.0M -1.0% | -$569.2M +6.2% | -$606.6M +14.2% | -$707.4M -55.8% | -$454.0M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $35.0M -1.5% | $35.5M +36.7% | $26.0M +42.7% | $18.2M +37.6% | $13.2M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 +100.0% | -$1.6M | $0 -100.0% | $48.7M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $153.0M -3.2% | $158.0M +16.9% | $135.2M +3.7% | $130.4M +24.2% | $105.0M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$23.0M -265.3% | $13.9M +192.2% | -$15.1M -125.1% | $60.2M +195.3% | -$63.2M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$31.0M +7.7% | -$33.6M -47.5% | -$22.8M -88.7% | -$12.1M -122.2% | -$5.4M | $592.6M | $1.3B | $626.2M |
| Inventory | -$6.0M +46.5% | -$11.2M -61.7% | -$6.9M +28.6% | -$9.7M -211.2% | -$3.1M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $24.0M -48.9% | $47.0M +1874.5% | $2.4M -97.0% | $79.8M +2746.5% | $2.8M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$10.0M -185.2% | $11.7M -4.1% | $12.2M +466.3% | $2.2M +103.8% | -$57.5M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | -$56.0M -6.7% | -$52.5M -314.5% | -$12.7M -110.7% | $118.1M +909.1% | $11.7M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$466.0M -12.5% | -$414.2M +12.8% | -$474.8M -24.8% | -$380.5M -12.3% | -$338.7M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$6.0M +19.9% | -$7.5M +84.0% | -$46.8M +68.0% | -$146.1M -99.9% | -$73.1M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 +100.0% | -$75.0M | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$186.0M +54.5% | -$408.6M +22.4% | -$526.4M +14.4% | -$614.7M +39.3% | -$1.0B | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $444.0M +7.4% | $413.3M -44.6% | $746.2M +36.9% | $545.1M -38.8% | $890.9M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$16.0M -7.1% | -$14.9M -97.9% | -$7.5M +75.5% | -$30.8M -3174.3% | -$942.0K | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | $236.0M +1428.2% | -$17.8M -110.6% | $168.0M +157.6% | -$291.7M -49.3% | -$195.4M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $392.0M | $0 | $0 | $0 | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $86.0M -77.4% | $381.0M +0.3% | $379.8M | $0 -100.0% | $78.9M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $0 -100.0% | $18.3M +117.7% | $8.4M -98.3% | $501.2M +1165.4% | $39.6M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $478.0M +19.7% | $399.2M +2.9% | $388.1M -22.6% | $501.2M +322.8% | $118.6M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $5.5M +316.4% | -$2.5M -646.5% | $462.0K +143.0% | -$1.1M +10.0% | -$1.2M | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $253.5M +819.3% | -$35.2M -143.1% | $81.8M +147.6% | -$172.0M +58.7% | -$416.7M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$472.0M -11.9% | -$421.7M +19.2% | -$521.6M +1.0% | -$526.6M -27.9% | -$411.8M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Centessa Pharmaceuticals plc
NASDAQ:CNTA
$6.15B
Apogee Therapeutics, Inc.
NASDAQ:APGE
$5.47B
CG Oncology, Inc. Common stock
NASDAQ:CGON
$5.25B
Travere Therapeutics, Inc.
NASDAQ:TVTX
$4.84B
Celcuity Inc.
NASDAQ:CELC
$4.32B
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
$4.11B
Dyne Therapeutics, Inc.
NASDAQ:DYN
$3.01B
Soleno Therapeutics, Inc.
SLNO
$2.76B
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
$2.55B
Ascentage Pharma Group International
NASDAQ:AAPG
$409.04M
SEC Filings
Recent regulatory filings
No filings found.
Does RARE generate free cash flow?
Ultragenyx Pharmaceutical Inc. (RARE) generated -$472,000,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does RARE produce?
Operating cash flow was -$466,000,000.00, before capital expenditures of $6.00M.
Explore More
Continue the stock analysis
Jump to another research area for this company.